A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
收藏DataCite Commons2026-01-21 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012681/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.
提供机构：
Vivli
创建时间：
2026-01-21
